Completed
PHASE3
INTERVENTIONAL
NCT01956110
Evidence-based Stimulation Trial With Human rFSH in Europe and Rest of World 1
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This trial investigates the effects of FE 999049 compared to GONAL-F.
Interventions
Name:
Follitropin Delta (FE 999049)
Type:
DRUG
Description:
Name:
Follitropin Alfa (GONAL-F)
Type:
DRUG
Description:
Primary Outcomes
Measure:
Ongoing Pregnancy Rate
TimeFrame:
10-11 weeks after blastocyst transfer
Description:
Ongoing pregnancy was defined as at least one intrauterine viable fetus 10-11 weeks after blastocyst transfer.
Measure:
Ongoing Implantation Rate
TimeFrame:
10-11 weeks after blastocyst transfer
Description:
Ongoing implantation rate was defined as the number of intrauterine viable fetuses 10-11 weeks after transfer divided by number of blastocysts transferred.
Trial Information
NCT ID
NCT01956110
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Ferring Pharmaceuticals
Last Updated
December 15, 2025